{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:53:29Z","timestamp":1774702409447,"version":"3.50.1"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100016469","name":"takeda pharmaceuticals international","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vedolizumab is a monoclonal antibody approved for adults with moderately to severely active ulcerative colitis and an inadequate response\/intolerance to conventional, or anti-tumor necrosis factor (TNF) treatment. Additional efficacy data for second-line vedolizumab after first-line anti-TNF treatment are required to determine its optimal position in the treatment sequence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate efficacy and health-related quality of life (HRQoL) associated with second-line vedolizumab after first-line anti-TNF in patients with ulcerative colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>Data from randomized, placebo-controlled phase III trials (GEMINI-1 (NCT00783718) and VISIBLE-1 (NCT02611830)) were used. Patients who received second-line vedolizumab after first-line anti-TNF treatment within 5\u2009years before trial enrollment were included. The primary outcome was clinical remission with two definitions based on the adapted Mayo score. Secondary outcomes were corticosteroid (CS)-free remission, Mayo endoscopic score (MES) \u2a7d1, and HRQoL (Inflammatory Bowel Disease Questionnaire and EuroQoL-5 Dimension Visual Analog Scale). Outcomes were assessed at Week 52. Efficacy of vedolizumab versus placebo was compared using fixed-effects models. Regression analyses assessed treatment effects, adjusting for disease location\/duration and previous CS use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 137 patients from GEMINI-1\/VISIBLE-1 were included. Patient characteristics were similar across cohorts, although mean disease duration ranged from 6.6 to 9.9\u2009years. Second-line vedolizumab was associated with a higher likelihood of achieving both definitions of clinical remission and all secondary outcomes (CS-free remission, MES \u2a7d1, and HRQoL) versus placebo. Regression analysis showed that patients treated with vedolizumab were 7.13\u201311.35 times more likely to achieve clinical remission (both definitions) versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Second-line vedolizumab after first-line anti-TNF treatment significantly increased the likelihood of achieving clinical remission, MES \u2a7d1, and improved HRQoL at Week 52 versus placebo in patients with ulcerative colitis. The small sample size, associated limitations, and heterogeneity observed in some outcomes warrant further research to strengthen these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261431467","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:40:06Z","timestamp":1774316406000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saint-Antoine Hospital, Assistance Publique-H\u00f4pitaux de Paris APHP, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Cheah","sequence":"additional","affiliation":[{"name":"OPEN Health HEOR &amp; Market Access, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-3310","authenticated-orcid":false,"given":"Patricia","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Global Medical Evidence, Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lytske","family":"Bakker","sequence":"additional","affiliation":[{"name":"OPEN Health HEOR &amp; Market Access, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Meyer","sequence":"additional","affiliation":[{"name":"Takeda Pharma AG, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.065"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231159452"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2022.00098"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02225-w"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad203"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0769"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.01.069"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_4_15_2","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya S","year":"2019","unstructured":"Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019; 14: e0212989.","journal-title":"PLoS One"},{"key":"e_1_3_4_16_2","unstructured":"US Food and Drug Administration. ENTYVIO\u00ae prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761359s000lbl.pdf (2025 accessed 2 January 2025)."},{"key":"e_1_3_4_17_2","unstructured":"European Medicines Agency. Entyvio summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/entyvio-epar-product-information_en.pdf (2025 accessed 2 January 2025)."},{"key":"e_1_3_4_18_2","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 2020; 158: 562\u2013572.e12.","journal-title":"Gastroenterology"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.11.014"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16193"},{"key":"e_1_3_4_21_2","article-title":"OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)","volume":"19","author":"Bouguen G","year":"2025","unstructured":"Bouguen G, Nachury M, Nancey S, et al. OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI). J Crohns Colitis 2025; 19: i74.","journal-title":"J Crohns Colitis"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_3_4_23_2","first-page":"2023","article-title":"Clinical trial design in ulcerative colitis: interpreting evolving endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 1 and VISIBLE 1","volume":"360","author":"Sandborn WJ","unstructured":"Sandborn WJ, Sands BE, Uddin S, et al. Clinical trial design in ulcerative colitis: interpreting evolving endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360 2023; 6: otad076.","journal-title":"Crohns Colitis"},{"key":"e_1_3_4_24_2","unstructured":"US Food and Drug Administration. Ulcerative colitis: developing drugs for treatment guidance for industry https:\/\/www.fda.gov\/media\/158016\/download (2022 accessed 13 March 2025)."},{"key":"e_1_3_4_25_2","unstructured":"US Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry https:\/\/www.fda.gov\/files\/drugs\/published\/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf (2022 accessed 20 March 2025)."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(89)80080-0"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.1.27"},{"key":"e_1_3_4_30_2","unstructured":"Deeks JJ Higgins JPT Altman DG et al. Analysing data and undertaking meta-analyses. In: Higgins JP Thomas J Chandler J et al. (ed.) Cochrane handbook for systematic reviews of interventions. Cochrane Training 2023. https:\/\/training.cochrane.org\/handbook\/current (accessed 16 December 2024)."},{"key":"e_1_3_4_31_2","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna Austria https:\/\/www.R-project.org\/ (2023 accessed 4 June 2025)."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/wics.147"},{"key":"e_1_3_4_33_2","unstructured":"Wickham HM Smith E Fay D. haven: import and export \u201cSPSS\u201d \u201cStata\u201d and \u201cSAS\u201d files. R package version 2.5.4 https:\/\/github.com\/tidyverse\/haven https:\/\/github.com\/WizardMac\/ReadStat https:\/\/haven.tidyverse.org (2023 accessed 30 January 2025)."},{"key":"e_1_3_4_34_2","article-title":"brglm2: Bias reduction in generalized linear models","author":"Kosmidis I.","unstructured":"Kosmidis I. brglm2: Bias reduction in generalized linear models. R package version 06.","journal-title":"R package version 06"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0906"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13852"},{"key":"e_1_3_4_38_2","article-title":"Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"19","author":"Katsoula A","year":"2025","unstructured":"Katsoula A, Paschos P, Malandris K, et al. Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life. J Crohns Colitis 2025; 19: jjaf210.","journal-title":"J Crohns Colitis"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.11.006"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261431467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261431467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261431467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:27:27Z","timestamp":1774700847000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261431467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["10.1177\/17562848261431467"],"URL":"https:\/\/doi.org\/10.1177\/17562848261431467","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17562848261431467"}}